Zoplar is a technology company.
Zoplar has raised $3.0M across 1 funding round.
Zoplar has raised $3.0M in total across 1 funding round.
Zoplar has raised $3.0M in total across 1 funding round.
Zoplar's investors include BEENEXT, Global Founders Capital.
# Zoplar: A Healthcare Technology Company
Zoplar is a B2B medical supply procurement platform that served small and medium-sized hospitals in India by simplifying access to medical devices and equipment.[1] Founded in 2022, the company positioned itself as a technology-driven solution to streamline hospital procurement processes, reduce inefficiencies, and enhance supply chain transparency.[1] Zoplar's core mission was to transform how healthcare institutions sourced medical supplies by offering a one-stop platform that addressed critical pain points including pricing complexity, inventory management, and reliable after-sales service.[3]
The company gained traction quickly, partnering with approximately 300 hospitals across the Delhi NCR region, including prominent nephrology chains such as DCDC, and achieved a 40% repeat customer rate—a strong indicator of market demand.[3] However, the startup's operations were short-lived, ceasing in February 2025 following a regulatory decision that fundamentally altered its business model.
Zoplar was founded in 2022 by Amit Sah and Umesh Sharma, two entrepreneurs with complementary backgrounds.[3][4] Amit brought extensive healthcare industry experience, while the co-founders had previously collaborated at OYO, providing a strong operational foundation.[3] The idea emerged from direct observation of MSME hospital struggles: these institutions faced significant challenges in identifying price-optimal medical equipment, managing relationships with multiple vendors, ensuring quality after-sales service, and accessing financing solutions.[3]
The founders conducted comprehensive research into these pain points and recognized a specific market opportunity: medium and small-sized hospitals relied heavily on refurbished medical devices to reduce costs.[4] Zoplar capitalized on this insight by procuring certified refurbished devices and bundling them with after-sales service—a combination that resonated strongly with its target market.
Zoplar operated within the broader healthtech and supply chain digitalization trend, addressing a critical gap in India's healthcare infrastructure.[3] The timing was favorable: India's healthcare sector was rapidly evolving, and MSME hospitals—which constitute a significant portion of India's healthcare delivery system—faced persistent inefficiencies in procurement and equipment access.
The company's approach reflected a growing recognition that healthcare infrastructure in emerging markets requires localized solutions tailored to cost constraints and operational realities. By focusing on refurbished devices rather than new equipment, Zoplar acknowledged the economic realities of India's hospital ecosystem while leveraging technology to add transparency and service quality.
Zoplar's shutdown in February 2025 illustrates the critical importance of regulatory alignment in healthcare technology ventures. The Central Drugs Standard Control Organisation's (CDSCO) decision to prohibit imports of second-hand or refurbished medical devices rendered Zoplar's core business model non-viable.[4] Despite strong operational momentum and successful Series A funding of $3.4 million led by Blume Ventures, the company made the decision to return capital to investors rather than pivot.[4]
The startup's trajectory—from promising market traction to regulatory-driven shutdown—underscores a broader lesson for healthtech entrepreneurs: regulatory frameworks in healthcare are non-negotiable constraints that must be thoroughly validated before scaling. While Zoplar's technology platform and customer relationships demonstrated genuine market demand, the regulatory environment ultimately determined viability. The company's experience may inform future approaches to medical device procurement in India, potentially spurring ventures that focus on new equipment distribution or alternative supply chain models that align with regulatory requirements.
Zoplar has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Series A in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $3.0M Series A | BEENEXT, Global Founders Capital |